261 related articles for article (PubMed ID: 29563634)
1. The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
Polena H; Creuzet J; Dufies M; Sidibé A; Khalil-Mgharbel A; Salomon A; Deroux A; Quesada JL; Roelants C; Filhol O; Cochet C; Blanc E; Ferlay-Segura C; Borchiellini D; Ferrero JM; Escudier B; Négrier S; Pages G; Vilgrain I
Br J Cancer; 2018 May; 118(9):1179-1188. PubMed ID: 29563634
[TBL] [Abstract][Full Text] [Related]
2. Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker.
Vilgrain I; Sidibé A; Polena H; Cand F; Mannic T; Arboleas M; Boccard S; Baudet A; Gulino-Debrac D; Bouillet L; Quesada JL; Mendoza C; Lebas JF; Pelletier L; Berger F
PLoS One; 2013; 8(12):e80056. PubMed ID: 24358106
[TBL] [Abstract][Full Text] [Related]
3. Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib.
Niinivirta M; Georganaki M; Enblad G; Lindskog C; Dimberg A; Ullenhag GJ
BMC Cancer; 2020 Apr; 20(1):339. PubMed ID: 32321460
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
5. Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
Rautiola J; Lampinen A; Mirtti T; Ristimäki A; Joensuu H; Bono P; Saharinen P
PLoS One; 2016; 11(4):e0153745. PubMed ID: 27100185
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.
Dufies M; Nollet M; Ambrosetti D; Traboulsi W; Viotti J; Borchiellini D; Grépin R; Parola J; Giuliano S; Helley-Russick D; Bensalah K; Ravaud A; Bernhard JC; Schiappa R; Bardin N; Dignat-George F; Rioux-Leclercq N; Oudard S; Négrier S; Ferrero JM; Chamorey E; Blot-Chabaud M; Pagès G
Theranostics; 2018; 8(9):2447-2458. PubMed ID: 29721091
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
8. Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site.
Wallez Y; Cand F; Cruzalegui F; Wernstedt C; Souchelnytskyi S; Vilgrain I; Huber P
Oncogene; 2007 Feb; 26(7):1067-77. PubMed ID: 16909109
[TBL] [Abstract][Full Text] [Related]
9. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
Paule B; Bastien L; Deslandes E; Cussenot O; Podgorniak MP; Allory Y; Naïmi B; Porcher R; de La Taille A; Menashi S; Calvo F; Mourah S
PLoS One; 2010 May; 5(5):e10715. PubMed ID: 20502715
[TBL] [Abstract][Full Text] [Related]
10. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
11. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation.
Lin MT; Yen ML; Lin CY; Kuo ML
Mol Pharmacol; 2003 Nov; 64(5):1029-36. PubMed ID: 14573751
[TBL] [Abstract][Full Text] [Related]
13. miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Khella HWZ; Butz H; Ding Q; Rotondo F; Evans KR; Kupchak P; Dharsee M; Latif A; Pasic MD; Lianidou E; Bjarnason GA; Yousef GM
Mol Ther; 2015 Nov; 23(11):1748-1758. PubMed ID: 26201448
[TBL] [Abstract][Full Text] [Related]
14. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
16. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.
Bastin J; Werbrouck E; Verbiest A; Punie K; Bechter O; Woei-A-Jin FJ; Wolter P; Wildiers H; Lerut E; Dumez H; Decallonne B; Clement P; Vanderschueren D; Albersen M; Oyen R; Schöffski P; Beuselinck B
Acta Clin Belg; 2019 Jun; 74(3):169-179. PubMed ID: 29774795
[TBL] [Abstract][Full Text] [Related]
18. Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma.
Trávníček I; Branžovský J; Kalusová K; Hes O; Holubec L; Pele KB; Ürge T; Hora M
Anticancer Res; 2015 Oct; 35(10):5661-6. PubMed ID: 26408740
[TBL] [Abstract][Full Text] [Related]
19. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
Minardi D; Lucarini G; Santoni M; Mazzucchelli R; Burattini L; Pistelli M; Bianconi M; Di Primio R; Scartozzi M; Montironi R; Cascinu S; Muzzonigro G
Anticancer Res; 2013 Nov; 33(11):5017-22. PubMed ID: 24222145
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma.
Wang B; Gu W; Wan F; Shi G; Ye D
Int Braz J Urol; 2019; 45(1):89-99. PubMed ID: 29570259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
